ISBN: 978-80-244-5740-6 | DOI: 10.5507/lf.20.24457406

Zásady antibiotické léčby

Milan Kolář, Dominik Rejman, Jan Bardoň


The textbook presents in an overview form uú-to-date information concerning antibiotic treatment from any points of view. These have been designed to facilitate orientation in the field of individual antibiotic groups and drugs, bacterial infections and their adequate antibiotic treatment. The main emphasis is put on the practical medical view, the clinical interpretation of the results of microbiological (especially bacteriological) examinations, the most important etiologigal agents in the most common community and nosocomial infections and the initial therapeutic approach, respectively antibiotherapy.

1. edition, Published: 2020, publisher: Univerzita Palackého v Olomouci, Křížkovského 8, 771 47 Olomouc



References

  1. Ambler RP. The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 1980, 289:321-331. Go to original source...
  2. American Thoracic Society and the Infectious Diseases Society of America. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am J Respir Crit Care Med 2005, 171:388-416. Go to original source...
  3. Arnan M, Gudiol C, Calatayud L, et al. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 2011, 30:355-360. Go to original source...
  4. Arozullah AM, Khuri SF, Henderson WG, Daley J, for the Participants in the National Veterans Affairs Surgical Quality Improvement Program. Development and validation of a multifactorial risk index for predicting postoperative pneumonia after major noncardiac surgery. Ann Intern Med 2001, 135:847-857. Go to original source...
  5. Asensio A, Alvarez-Espejo T, Fernandes-Crehuet J, et al. Trends in yearly prevalence of third-generation cephalosporin and fluoroquinolone resistant Enterobacteriaceae infections and antimicrobial use in Spanish hospitals, Spain, 1999 to 2010. Euro Surveill 2011, 16:pii=19983. Go to original source...
  6. Balali-Mood M, Moshiri M, Etemad L. Medical aspects of bio-terrorism. Toxicon 2013, 69:131-142. Go to original source...
  7. Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance. Report of the national nosocomial resistence surveillance group. Diag Microbiol Infect Dis 1992, 15:37-42. Go to original source...
  8. Barber M, Rozwadovska-Dowzenko M. Infection by penicillin-resistant staphylococci. Lancet 1948, 255:641-644. Go to original source...
  9. Barbosa TM, Levy SB. The impact of antibiotic use on resistance development and persistence. Drug Resist Updat 2000, 3:303-311. Go to original source...
  10. Bardoň J. Alimentární infekce způsobené baktériemi. Klin Mikrobiol Inf Lék 2009, 15:26-30.
  11. Bardoň J. Bakteriální zoonózy ve 21. století. Veterinářství 2013, 63:573-577.
  12. Bardoň J, Kohnová I, Prokeš Z, Skalka P, Bzdil J. Přímý průkaz původce maltské horečky - kasuistika. Klin Mikrobiol Inf Lék 2011, 17:50-54.
  13. Bardoň J, Koláčková I, Husičková V, et al. Výskyt a charakteristika termotolerantních kampylobakterů v potravinovém řetězci člověka. Epidemiol Mikrobiol Imunol 2014, 63: 232-237.
  14. Bardoň J, Kolář M, Karpíšková R, Hricová K. Prevalence of thermotolerant Campylobacter spp. in broilers at retail in the Czech Republic and their antibiotic resistance. Food Control 2011, 22:328-332. Go to original source...
  15. Bardoň J, Ondrušková O, Ambrož P. Výskyt salmonel v mase a masných výrobcích na Moravě v letech 2010 až 2015. Klin Mikrobiol Inf Lék 2016, 22:48-53.
  16. Bardoň J, Pijáček M, Harna J, et al. Brucella suis - málo známé zoonotické agens. Klin Mikrobiol Inf Lék 2012, 18:53-54.
  17. Beneš J. Antibiotika, systematika, vlastnosti, použití. Praha, Grada Publishing 2018.
  18. Beneš J. a kol. Infekční lékařství. Praha, Galén 2009.
  19. Beneš J, Džupová O. Tigecyklin: Zařazení mezi ostatními antibiotiky, vlastnosti, klinické využití. Klin Mikrobiol Inf Lék 2009, 15:7-13.
  20. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655. Go to original source...
  21. Bořilová G. Termotolerantní Campylobacter spp. In: Kameník a kol. Maso jako potravina. Veterinární a farmaceutická univerzita Brno. Brno. 2014:152-166.
  22. Bouza E, Perez A, Munoz P, et al. Ventilator-associated pneumonia after heart-surgery: A prospective analysis and the value of surveillance. Crit Care Med 2003, 31:1964-1970. Go to original source...
  23. Bulkowstein S, Ben-Shimol S, Givon-Lavi N, et al. Comparison of early onset sepsis and community-acquired late onset sepsis in infants less than 3 months of age. Pediatrics 2016, 16:82. Go to original source...
  24. Bush K, Jacoby GA. Updated functional classification of β-Lactamases. Antimicrob Agents Chemother 2010, 54:969-976. Go to original source...
  25. Buzby JC, Roberts T. Economic costs and trade impacts of microbial foodborne illness. World Health Stat Q 1997, 50:57-66.
  26. Cascio A, Bosilkovski M, Rodriguez-Morales AJ, Pappas G. The socio-ecology of zoonotic infections. Clin Microbiol Infect 2011, 17:336-342. Go to original source...
  27. Cattoir V, Leclercq R. Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce? J Antimicrob Chemother 2013, 68:731-742. Go to original source...
  28. Chevalier J, Bredin J, Mahamoud A, et al. Inhibitors of antibiotic efflux in resistant Enterobacter aerogenes and Klebsiella pneumoniae strains. Antimicrob Agents Chemother 2004, 48:1043-1046. Go to original source...
  29. Conlan JW. Francisella tularensis: A red-blooded pathogen. J Infect Dis 2011, 204:6-8. Go to original source...
  30. Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998, 129:433-440. Go to original source...
  31. Cortese F, Scicchitano P, Gesualdo M, et al. Early and late infections in newborns: where do we stand? A review. Pediatr Neonatol 2016, 57:265-273. Go to original source...
  32. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165:867-903. Go to original source...
  33. Craven D, Palladino R, Mcquillen D. Healthcare-associated pneumonia in adults: management principles to improve outcomes. Infect Dis Clin North Am 2004, 18:939-962. Go to original source...
  34. Dalhoff K, Ewig S. Adult patients with nosocomial pneumonia: epidemiology, diagnosis, and treatment. Dtsch Arztebl Int 2013, 110:634-640. Go to original source...
  35. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign guidelines committee including the pediatric subgroup surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock 2012. Intensive Care Med 2013, 39:165-228. Go to original source...
  36. Dong Y, Speer CP. Late-onset neonatal sepsis: recent developments. Arch Dis Child - Fetal Neonatal Ed 2015, 100:257-263. Go to original source...
  37. Doubravská L, Uvízl R, Gabrhelík T, Klementová O, Kolář M. Nozokomiální pneumonie ve světle aktuálních doporučení - je prostor pro zlepšení péče o pacienta? Klin Mikrobiol Inf Lék 2018, 24:4-9.
  38. Doubravská L, Uvízl R, Herkel T, et al. Detection of the etiological agents of hospital-acquired pneumonia - validity and comparison of different types of biological sample collection: A prospective, observational study in intensive care patients. Epidemiol Mikrobiol Imunol 2017, 66:155-162.
  39. Douglas I. Pulmonary infections in critical/intensive care - rapid diagnosis and optimizing antimicrobial usage. Curr Opin Pulm Med 2017, 23:198-203. Go to original source...
  40. Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. Clin Microbiol Rev 2010, 23:160-201. Go to original source...
  41. Duggirala AV, Chen FM, Gergen PJ. Postoperative Adverse Events in Teaching and Nonteaching Hospitals. Fam Med 2004, 36:508-513.
  42. Dulguerov P, Gysin C, Perneger TV, Chevrolet JC. Percutaneous or surgical tracheostomy: A meta analysis. Crit Care Med 1999, 27:1617-1625. Go to original source...
  43. EFSA (European Food Safety Authority) and ECDC (European Centre for Disease Prevention and Control), 2017. The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2016. EFSA Journal 2017, 15. Go to original source...
  44. EFSA (European Food Safety Authority). Scientific opinion of the panel on BIOHAZ on a request from EFSA on monitoring and identification of human enteropathogenic Yersinia spp. EFSA Journal 2007, 5.
  45. EFSA (European Food Safety Authority) and ECDC (European Centre for Disease Prevention and Control), 2019. The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2017. EFSA Journal 2019, 17. Go to original source...
  46. Státní zdravotní ústav Praha. Informační systém infekčních nemocí (ISIN).
  47. European Centre for Disease Prevention and Control. European Antimicrobial Resistance Surveillance Network (EARS-Net).
  48. European Committee on Antimicrobial Susceptibility Testing - EUCAST.
  49. Garneau-Tsodikova S, Labby KJ. Mechanisms of resistance to aminoglycoside antibiotics: overview and perspectives. Med Chem Comm 2015, 7:11-27. Go to original source...
  50. Fang G, Araujo V, Guerrant RL. Enteric infections associated with exposure to animals or animal products. Infect Dis Clin North Am 1991, 5:681-701. Go to original source...
  51. Ferrer M, Liapikou A, Valencia M, et al. Validation of the american thoracic society-infectious diseases society of america guidelines for hospital-acquired pneumonia in the intensive care unit. Clin Infect Dis 2010, 50:945-952. Go to original source...
  52. Gabrhelík T, Hanulík V, Jakubec P, et al. Porovnání validity různých vzorků biologického materiálu z dýchacích cest a jejich přínosu v detekci původců nozokomiální pneumonie. Klin mikrobiol inf Lék 2015, 21:4-9.
  53. Gao R, Hu Y, Li Z, et al. Dissemination and mechanism for the mcr-1 colistin resistance. PLOS Pathog 2016, 12:e1005957. Go to original source...
  54. Gelbíčová T, Baráková A, Florianová M, Karpíšková R. Nález Acinetobacter baumannii s rezistencí ke kolistinu s genem mcr-4. Klin Mikrobiol Inf Lék 2019, 25:4-6.
  55. Giamarellos-Bourboulis EJ, Papadimitriou E, Galanakis N, et al. Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. Int J Antimicrob Agents 2006, 27:476-481. Go to original source...
  56. Gould LH, Pape J, Ettestad P, Griffith KS, Mead PS. Dog-associated risk factors for human plague. Zoonoses Public Health 2008, 55:448-454.
  57. Grusson D, Hilbert G, Vargas F, et al. Rotation and restricted use of antibiotics in a medical intensive care unit. Am J Respir Crit Care Med 2000, 162: 837-843. Go to original source...
  58. Gupta R, Malik A, Rizvi M, et al. Epidemiology of multidrug-resistant Gram-negative pathogens isolated from ventilator-associated pneumonia in ICU patients. J Glob Antimicrob Resist 2017, 9:47-50. Go to original source...
  59. Hanulík V, Htoutou Sedláková M, Uvízl R. Bakteriální původci pneumonií u pacientů v intenzivní péči. Klin Mikrobiol Inf Lek 2011, 17:134-139.
  60. Herkel T, Uvízl R, Doubravská L, et al. Epidemiology of hospital-acquired pneumonia: results of a Central European multicenter, prospective, observational study compared with data from the European region. Biomed Papers 2016, 160:448-455. Go to original source...
  61. Horáková M, Ľubušká L, Kolář M, et al. Individualized prophylaxis in patients with esophageal replacement because of cancer. Surg Inf 2015, 16:513-517. Go to original source...
  62. Htoutou Sedlákova M, Hanulík V, Chromá M, et al. Phenotypic detection of broad-spectrum beta-lactamases in microbiological practice. Med Sci Monit 2011, 17:147-152. Go to original source...
  63. Htoutou Sedláková M, Pudová V, Kolář M a pracovní skupina. Bakteriální původci nozokomiálních pneumonií - multicentrická studie v České republice. Klin Mikrobiol Inf Lék 2015, 21:10-14.
  64. Htoutou Sedláková M, Urbánek K, Vojtová V, et al. Antibiotic consumption and its influence on the resistance in Enterobacteriaceae. BMC Res Notes 2014, 7:454. Go to original source...
  65. Hulánková R. Salmonela spp. In: Kameník a kol. Maso jako potravina. Veterinární a farmaceutická univerzita Brno. Brno. 2014:139-152.
  66. Hulánková R. Listeria monocytogenes. In: Kameník a kol. Maso jako potravina. Veterinární a farmaceutická univerzita Brno. Brno. 2014:166-178.
  67. Hulánková R. Enteropatogenní yersinie. In: Kameník a kol. Maso jako potravina. Veterinární a farmaceutická univerzita Brno. Brno. 2014:191-207.
  68. Huong TT, Komínková M, Guráň R, et al. Identifikace mikroorganismů pomocí MALDI-TOF MS. J Metallomics Nanotechnol 2014, 1:64-66.
  69. Husa P. Leptospiróza. Vnitř Lék 2012, 58:631-632.
  70. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165:867-902. Go to original source...
  71. Chastre J, Trouillet JL, Combes A, Luyt CE. Diagnostic techniques and procedures for establishing the microbial etiology of ventilator-associated pneumonia for clinical trials: the pros for quantitative cultures. Clin Infect Dis 2010, 51:S88-S92. Go to original source...
  72. Ibrahim EH, Ward S, Sherman G, Kollef MH. A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting. Chest 2000, 117:1434-1442. Go to original source...
  73. Iregui M, Ward S, Sherman G, Fraser V, Kollef M: Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002, 122:262-268. Go to original source...
  74. Ioanas M, Cavalcanti M, Ferrer M, et al. Hospital-acquired pneumonia: coverage and treatment adequacy of current guidelines. Eur Respir J 2003, 22:876-882. Go to original source...
  75. Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: medical and public health management. JAMA 2000, 283:2281-2290. Go to original source...
  76. Jindrák V, Henyšová J, Vaniš V, Urbášková P, Litoš P. Rezistence Streptococcus pyogenes k erytromycinu jako regionální problém. Klin Mikrobiol Inf Lék 1999, 5:237-243.
  77. Kahn LH. Managing zoonotic disease risk: Need for greater physician and veterinarian collaboration. J Chin Clin Med 2007, 2:105-109.
  78. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016, 63:61-111. Go to original source...
  79. Kameník J. Maso jako vehikulum bakteriálních původců alimentárních onemocnění. In: Kameník J. a kol. Maso jako potravina. Veterinární a farmaceutická univerzita Brno. Brno. 2014:130-138.
  80. Kang CI, Chung DR, Ko KS, et al. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteriemia in patients with hematologic malignancy. Ann Hematol 2012, 91:115-121. Go to original source...
  81. Kesselová M, Kolář M, Sauer P, et al. Molekulárně-biologická analýza ESBL-pozitivních kmenů Klebsiella pneumoniae na novorozeneckém oddělení Fakultní nemocnice Olomouc. Klin Mikrobiol Inf Lék 2005, 11:20-24.
  82. Kolář M. Antibiotická léčba bakteriálních infekcí respiračního traktu u dospělých pacientů v komunitě. Int Med Prax 2000, 2:395-396.
  83. Kolář M. Interpretace bakteriální citlivosti/rezistence k antibiotikům. Klin Mikrobiol Inf Lék 2016, 22:105-109.
  84. Kolář M. Problematika bakteriální rezistence k antibiotické léčbě. Postgrad Med 2013, 15:817-821.
  85. Kolář M. Problematika vankomycin-rezistentních enterokoků. Klin Mikrobiol Inf Lék 2018, 24:50-56.
  86. Kolář M. Respirační infekce a jejich léčba. Praha, Maxdorf Jessenius 2016.
  87. Kolář M. Volba antibiotik v intenzivní péči. Postgrad Med 2012, 14:510-513.
  88. Kolář M. Zásady antibiotické léčby. Rozhled Chir 2019, 98:137-144. Go to original source...
  89. Kolář M, Hanulík V, Chromá M. Účinek tigecyklinu na vybrané multirezistentní bakterie. Klin Mikrobiol Inf Lék 2009, 15:4-6.
  90. Kolář M, Htoutou Sedláková M, Kantor L, Imwensi OP. Antibiotická léčba novorozeneckých bakteriálních infekcí. Neonatol Listy 2016, 22:12-15.
  91. Kolář M, Htoutou Sedláková M, Pudová P, et al. Incidence of fecal Enterobacteriaceae producing broad-spectrum beta-lactamases in patients with hematological malignancies. Biomed Papers 2015, 159:100-103. Go to original source...
  92. Kolář M, Htoutou Sedláková M, Suchánková H, Hanulík V. Vliv selekčního tlaku karbapenemů na bakteriální rezistenci. Klin Mikrobiol Inf Lék 2013, 19:4-7.
  93. Kolář M, Látal T, Čermák P. Klinicko-mikrobiologické podklady racionální antibiotické léčby. Praha, Trios 2002.
  94. Kolář M, Štrbová P. Vývoj rezistence invazivních bakterií v souvislosti se spotřebou antibiotik. Klin Farmakol Farmac 2015, 29:49-52.
  95. Kolář M, Urbánek K, Čekanová L, Koukalová D. Rezistence Streptococcus pyogenes k erytromycinu - závažný problém komunitních bakteriálních infekcí. Klin Farmakol Farm 2001, 15:13-16.
  96. Kolář M, Urbánek K, Látal T. Antibiotic selective pressure and development of bacterial resistance. International J Antimicrob Agents 2001, 17:357-363. Go to original source...
  97. Kolář M, Urbánek K, Vágnerová I, Koukalová D. The influence of antibiotic use on the occurrence of vancomycin-resistant enterococci. J Clin Pharm Therap 2006, 31:67-72. Go to original source...
  98. Kolář M, Vágnerová I, Kohnová I. Záchyt vankomycin- rezistentních enterokoků ve Fakultní nemocnici v Olomouci. Klin Mikrobiol Inf Lék 1997, 3:189-191.
  99. Kolek V, Kašák V, Vašáková M. Pneumologie. 2. rozš. vyd. Praha, Maxdorf Jessenius 2014.
  100. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections. A risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474. Go to original source...
  101. Kumarasamy KK, Toleman M, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010, 10:597-602. Go to original source...
  102. Lawson AJ. Campylobacteriosis. In: Palmer SR, Soulsby L, Torgerson PR, Brown DWG. Oxford Textbook of Zoonoses. 2. vyd. Oxford; Oxford University Press. 2011:136-145.
  103. Leone M, Bourgoin A, Cambon S, et al. Empirical antimicrobial therapy of septic shock patients: Adequacy and impact on the outcome. Crit Care Med 2003, 31:462-467. Go to original source...
  104. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference. Intensive Care Med 2003, 29:530-538. Go to original source...
  105. Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2016, 16:161-168. Go to original source...
  106. Luna CM, Aruj P, Niederman MS, et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 2006, 27:158-164. Go to original source...
  107. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997, 111:676-685. Go to original source...
  108. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18:268-281. Go to original source...
  109. Marešová V, Urbášková P. Daptomycin - nové antibiotikum pro léčbu závažných infekcí způsobených některými grampozitivními bakteriemi. Klin Farmakol Farm 2010, 24:187-189.
  110. Martin-Loeches I, Deja M, Koulenti D, et al. Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med 2013, 39:672-681. Go to original source...
  111. Martin-Loeches I, Torres A, Rinaudo M, et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. J Infect 2015, 70:213-222. Go to original source...
  112. Marvanová T, Kodym P. Laboratorní diagnostika leptospirózy. Zprávy CEM 2013, 22:204-205.
  113. McLauchlin J. Listeriosis. In: Palmer SR, Soulsby L, Torgerson PR, Brow, DWG. Oxford Textbook of Zoonoses. 2. vyd. Oxford; Oxford University Press 2011:117-127. Go to original source...
  114. Meletis G, Exindari M, Vavatsi N, Sofianou D, Diza E. Mechanisms responsible for the emergence of carbapenem resistance in Pseudomonas aeruginosa. Hippokratia 2012, 16:303-307.
  115. Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005, 49:1306-1311. Go to original source...
  116. Mihál V. Mimostřevní salmonelové infekce. Pediatr Prax 2004, 4:181-184.
  117. Mlynárčik P, Kolář M. Molecular mechanisms of polymyxin resistance and detection of mcr genes. Biomed Papers 2019, 163:28-38. Go to original source...
  118. Nencka R. Základní principy výzkumu nových léčiv. Olomouc, Univerzita Palackého v Olomouci, 2015.
  119. Neoral C, Horaková M, Aujesky R, et al. Infectious complications after esophagectomy. Surg Infect 2012, 13:159-162. Go to original source...
  120. Neu HC. The crisis in antibiotic resistance. Science 1992, 257:1064-1073. Go to original source...
  121. Nseir S, Di Pompeo C, Pronnier P, et al. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome. Eur Respir J 2002, 20:1483-1489. Go to original source...
  122. Nseir S, Di Pompeo C, Soubrier S, et al. Effect of ventilator-associated tracheobronchitis on outcome in patients without chronic respiratory failure: A case-control study. Crit Care 2005, 9:R238-R245. Go to original source...
  123. Pagani L, Dell'Amico E, Migliavacca R, et al. Multiple CTX-M-type extended-spectrum -lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in northern Italy. J Clin Microbiol 2003, 41:4264-4269. Go to original source...
  124. Palmer SR. The global challenge of zoonoses control. In: Palmer SR, Soulsby L, Torgerson PR, Brown DWG. Oxford Textbook of Zoonoses. 2. vyd. Oxford; Oxford University Press, 2011:263-274. Go to original source...
  125. Papajk J, Uvízl R, Kolář M. Vliv předchozí antibiotické terapie na epidemiologii ventilátorových pneumonií. Klin Mikrobiol Inf Lék 2019, 25:7-11.
  126. Paterson GK, Harrison EM, Holmes MA. The emergence of mecC methicillin-resistant Staphylococcus aureus. Trends Microbiol 2014, 22:42-47. Go to original source...
  127. Peacock SJ, Paterson GK. Mechanisms of methicillin resistance in Staphylococcus aureus. Annu Rev Biochem 2015, 84:577-601. Go to original source...
  128. Pearson A. Tularaemia. In: Palmer SR, Soulsby L, Torgerson PR, Brown DWG. Oxford Textbook of Zoonoses. 2. vyd. Oxford; Oxford University Press, 2011:263-274. Go to original source...
  129. Pejčoch M, Pavlíčková Z, Klapušová P. Epidemiologický potenciál zvířecích exkrementů v prostředí města Brna. Veterinářství 2009, 59:406-410.
  130. Piskin N, Aydemir H, Oztoprak N, et al. Inadequate treatment of ventilator-associated and hospital-acquired pneumonia: Risk factors and impact on outcomes. BMC Infect Dis 2012, 12:268. Go to original source...
  131. Planquette B,Timsit JF, Misset BY, et al. Pseudomonas aeruginosa ventilator-associated pneumonia: predictive factors of treatment failure. Am J Respir Crit Care Med 2013, 188:69-76. Go to original source...
  132. Prats E, Dorca J, Pujol M, et al. Effects of antibiotics on protected specimen brush sampling in ventilator-associated pneumonia. Eur Respir J 2002, 19:944-951. Go to original source...
  133. Průcha M, Fedora M, Kieslechová E, Šrámek V, et al. Sepse. Praha, Maxdorf Jesenius 2015.
  134. Pudová V, Htoutou Sedláková M, Kolář M and working group. Clonality of bacterial pathogens causing hospital-acquired pneumonia. Curr Microbiol 2016, 73:312-316. Go to original source...
  135. Prentice MB. Yersiniosis and plague. In: Palmer SR, Soulsby L, Torgerson PR, Brown DWG. Oxford Textbook of Zoonoses. 2. vyd. Oxford; Oxford University Press, 2011:232-246. Go to original source...
  136. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994, 150:1545-1549. Go to original source...
  137. Rello J, Gallego M, Marshal D, et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997, 156:196-200. Go to original source...
  138. Restrepo M, Peterson J, Fernandez JF, et al. Comparison of the bacterial etiology of early-onset and late-onset ventilator-associated pneumonia in subjects enrolled in 2 large clinical studies. Resp Care 2013, 58:1220-1225. Go to original source...
  139. Russell AR. Neonatal sepsis. Paediatr Child Health 2011, 21:265-269. Go to original source...
  140. Rybka A, Szanyi J, Kapla J, Plíšek S. Vysoce nebezpečné nákazy s mezilidským přenosem. Klin Mikrobiol Inf Lék 2012, 18:180-183.
  141. Safdar N, Defzulian C, Collard H, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: A systematic review. Crit Care Med 2005, 33:2184-2193. Go to original source...
  142. Satlin MJ, Calfee DP, Chen L, et al. Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma 2013, 54:799-806. Go to original source...
  143. Scaglione F, Paraboni L. Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection. Expert Rev Antiinfect Ther 2006, 4:479-490. Go to original source...
  144. Scharfen J. Diferenciální diagnostika v klinické mikrobiologii. Nucleus HK, 2013.
  145. Seppäla H, Nissinen A, Jarvinen H, et al. Resistance to erythromycin in group A streptococci. N Engl J Med 1992, 326:292-297. Go to original source...
  146. Seppäla H, Nissinen A, Yu Q, et al. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J Antimicrob Chemother 1993, 32:885-891. Go to original source...
  147. Shah BA, Padbury JF. Neonatal sepsis: an old problem with new insights. Virulence 2014, 5:170-178. Go to original source...
  148. Shane AL, Sanchez P, Stol BJ. Neonatal sepsis. Lancet 2017, 390:1770-1780. Go to original source...
  149. Scharfen J. Diferenciální diagnostika v klinické mikrobiologii. Praha, Nucleus HK 2013.
  150. Scharff RL, Mc Dowell J, Medeiros L. Economic costs of foodborne illness in Ohio. J Food Prot 2009, 72:128-136. Go to original source...
  151. Sifaoui F, Arthur M, Rice L, et al. Role of penicillin-binding protein 5 in expression of ampicillin resistance and peptidoglycan structure in Enterococcus faecium. Antimicrob Agents Chemother 2001, 45:2594-2597. Go to original source...
  152. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011, 24:71-109. Go to original source...
  153. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016, 315:801-810. Go to original source...
  154. Smith RM, Zochowski WJ. Leptosirosis. In: Palmer SR, Soulsby L, Torgerson PR, Brown DWG. Oxford Textbook of Zoonoses. 2. vyd. Oxford; Oxford University Press, 2011:224-231.
  155. Souweine B, Veber B, Bedos JP, et al. Diagnostic accuracy of protected specimen brush and bronchoalveolar lavage in nosocomial pneumonia: impact of previous antimicrobial treatments. Crit Care Med 1998, 26:236-244. Go to original source...
  156. Straková L, Motlová J. Active surveillance of early onset disease due to group B streptococci in newborns. Indian J Med Res 2004, 119:205-207.
  157. Šimetka O, Petros M, Podešvová H. Prevention of early-onset neonatal group B streptococcal infection: neonatal outcome after introduction of national screening guideline. Čes Gynekol 2010, 75:41-46.
  158. Tejada AA, Bello DS, Chaón VE, et al. Risk factors for nosocomial pneumonia in critically ill trauma patients. Crit Care Med 2001, 29:304-309. Go to original source...
  159. Threllfal EJ, Wain J, Lane C. Salmonellosis. In: Palmer SR, Soulsby L, Torgerson PR, Brown DWG. Oxford Textbook of Zoonoses. 2. vyd. Oxford; Oxford University Press, 2011:252-262. Go to original source...
  160. Torres A, Ewig S, Lode H, Carlet J. Defining, treating and preventing hospital acquired pneumonia: European perspective. Intensive Care Med 2009, 35:9-29. Go to original source...
  161. Torres A, Niederman M, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. Eur Respir J 2017, 50:1-26. Go to original source...
  162. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-ß-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007, 51:1987-1994. Go to original source...
  163. Urbánek K, Kolář M, Čekanová L. Utilisation of macrolides and the development of Streptococcus pyogenes resistance to erythromycin. Pharm World Sci 2005, 27:104-107. Go to original source...
  164. Urbánek K, Kolář M, Lovečková Y, Strojil J, Šantavá L. Influence of 3rd generation cephalosporin utilization on the occurrence of ESBL-positive Klebsiella pneumoniae strains. J Clin Pharm Therap 2007, 32:403-408. Go to original source...
  165. Urbánek K, Kolář M, Strojil J, et al. Utilization of fluoroquinolones and Escherichia coli resistance in urinary tract infection: inpatients and outpatients. Pharmacoepidemiol Drug Safety 2005, 14:741-745. Go to original source...
  166. Urbášková P, Jakubů V, Melter O. Analýza rezistence Streptococcus pyogenes k antibiotikům ze skupiny makrolidů. Zprávy CEM 2004, 13:28-29.
  167. Uttley AHC, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988, 1:57-58. Go to original source...
  168. Uvízl R, Hanulík V, Husičková V, et al. Hospital-acquired pneumonia in ICU patients. Biomed Papers 2011, 155:373-378. Go to original source...
  169. Uvízl R, Adamus M, Černý V, et al. Patient survival, predictive factors and disease course of severe sepsis in Czech intensive care units: a multicentre, retrospective, observational study. Biomed Papers 2016, 160:287-297. Go to original source...
  170. Uvízl R, Hanulík V, Husičková V, et al. Hospital-acquired pneumonia in icu patients. Biomed Papers 2011, 155:373-378. Uvízl R, Herkel T, Kolář M a pracovní skupina. Nozokomiální pneumonie - optimální nastavení iniciální empirické antimikrobiální terapie. Int med prax 2017, 19:203, e1-e5. Go to original source...
  171. Vincent JL. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329. Go to original source...
  172. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care (EPIC) study. EPIC International Advisory Committee. JAMA 1995, 274:639-644. Go to original source...
  173. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34:344-353. Go to original source...
  174. Votava M. Lékařská mikrobiologie - vyšetřovací metody. Brno, Neptun 2010.
  175. Walsh TR, Toleman MA. The emergence of pan-resistant Gram-negative pathogens merits a rapid global political response. J Antimicrob Chemother 2012, 67:1-3. Go to original source...
  176. Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003, 31:1312-1317. Go to original source...
  177. Weir M, Rajić A, Dutil L, Uhland C, Bruneau N. Zoonotic bacteria and antimicrobial resistance in aquaculture: Opportunities for surveillance in Canada. Can Vet J 2012, 53: 619-622.
  178. Werarak P, Kiratisin P, Thamlikitkul V. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance. J Med Assoc Thai 2010, 93 (Suppl. 1):126-138.
  179. Zhanel GG, Homenuik K, Nichol K. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004, 64:63-88. Go to original source...